Visiongain has published a new report on “Cancer Diagnostics Market Report Forecast of 2021 to 2031”. Forecasts by Test Type {(Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, BRCA Tests, CA-19 Tests, CEA Tests, HER2 Tests, KRAS Mutation Tests, ALK Tests, EGFR Mutation Tests, Others); Imaging (Mammography, Ultrasound, PET Scan, MRI Scan, CT Scan, SPECT & Others), Biopsy (Endoscopic Biopsy, Needle Biopsy, Bone Marrow Biopsy, Others), Immunohistochemistry, Liquid Biopsy, In Situ Hybridization}; Cancer Type (Lung Cancer, Melanoma, Breast Cancer, Colorectal Cancer, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others); End-User (Hospital Associated Labs, Diagnostic Imaging Centers, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users); by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Leading Regional/ Country market analysis, PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/cancer-diagnostics-market-2021/#download_sampe_div
COVID-19 Impact on Cancer Diagnostics Market
COVID-19 pandemic is one of the most unprecedented situations, the world has faced nearly in a century. Due to the rapid transmittal of the disease, there has been a sharp increase in number of cases worldwide. While some countries have crossed their peak and are returning to normal, many others are seeing ever-rising numbers. Growing funding from governments and companies can help combat this highly contagious disease. There are some sectors that are struggling while others are thriving. Overall, almost every industry including global cancer diagnostic market is anticipated to be hit by the pandemic. Increasing adoption of telehealth, current scale of COVID-19 vaccination, increasing efforts put by pharma companies for COVID treatment and high investment by government bodies are expected to help this market to recover soon.
Rising Funding for Cancer Research to Augur Cancer Diagnostics Market Growth
Governments in countries such as the U.S. are raising funds to assist cancer research. Clinical studies are also sponsored by governments to enable businesses to build successful cancer screening tests. The U.S. government allocated US$ 5.8 billion for cancer research and training to the National Cancer Institute (NCI), a federal government agency for FY 2018 to FY 2020. As opposed to the previous year, the budget rose by 5.3 percent. This is anticipated to fuel cancer diagnostics market growth over the forecast period from 2021 to 2031.
Inclusion of Cancer Screening Tests in National Screening Programs
Early cancer detection requires appropriate diagnostic procedures to screen an asymptomatic population at an average cancer risk, particularly for breast cancer, cervical cancer, colon cancer and melanoma. Introduction of routine mammography by major developed economies where breast cancer incidence is high have added cancer screening test in national cancer programs. For example, the U.S. government has combined the national cancer screening services with the national mammography program. This is projected to offer lucrative growth opportunities for the market players over the forecast period.
Get Detailed TOC @ https://www.visiongain.com/report/cancer-diagnostics-market-2021/#download_sampe_div
Competitive Landscape
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global cancer diagnostics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the cancer diagnostics market. Some of the companies profiled in this report are mentioned below:
- Abbott
- Agilent Technologies, Inc.
- Bio Rad Laboratories Inc.
- BioMark Diagnostics Inc.
- BD
- Hoffmann-La Roche Ltd.
- GE Healthcare
- Genomic Health (Exact Sciences Corporation)
- Hologic, Inc.
- Illumina, Inc.
- Koninklijke Philips N.V.
- QIAGEN
- Quest Diagnostics
- Siemens AG
- Thermo Fisher Scientific Inc.
- Toshiba Medical Systems Corporation
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the cancer diagnostic market and leading companies. You will find data, trends and predictions.
Find more Visiongain research reports on Pharma Diagnostics Sector click on the following links:
- Biologics Market
- Cancer Diagnostics Market
- Ovarian Cancer Drugs Market
- Women's Health Diagnostics Market
- Companion Diagnostics (CDx) Market
- Cancer Supportive Care Drugs Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.
